Paxil Suicide and Suicide Attempt Cases
The firm has been litigating Paxil suicide and suicide attempt cases for the past several years and has a number of cases pending in courts across the United States. Baum Hedlund has collected hundreds of thousands of pages of internal GSK documents and conducted dozens of depositions of GSK executives, employees, physicians, researchers and academics. As a result, we know how GSK operates, we know its tactics, the key players and how to get the evidence needed to effectively litigate cases for Paxil injuries or wrongful death against GSK.
We have seen the harm antidepressants can cause and the extent to which drug companies will go to protect their enormously profitable drugs and we and our clients have testified about this to the FDA. Baum Hedlund has accumulated a considerable body of evidence demonstrating that Paxil is associated with an increased risk of suicidality in all age groups, not just children and young adults, and that GSK was aware of the risk and yet chose not to warn the public of this serious risk. Instead, GSK over promoted the benefits of the drug while downplaying the risks.
On October 15, 2004, the FDA asked antidepressant manufacturers to add a black box warning to their labels to alert health care providers to an increased risk of suicidality caused by antidepressants in children and adolescents. On May 2, 2007, the FDA announced that it had asked antidepressant manufacturers to expand the current black box warnings concerning the increased risk of suicidality in children and adolescents to include young adults, but only ages 18 to 24. Based on our own 18-year investigation into the harmful side effects of antidepressants, we believe this warning should include people of all ages.